Products

FEops HEARTguideTM
FEops
Cardiology AI
FEops HEARTguide™ is a cloud-based AI and digital twin platform for structural heart procedure planning, providing predictive simulations and anatomical insights to optimize device sizing and positioning for interventions like TAVI and LAAO.

See all 1 product →

About FEops nv

FEops nv is a healthcare AI company that specializes in revolutionizing personalized treatment for patients with structural heart disease. They achieve this through their cloud-based platform, FEops HEARTguide™, which leverages predictive simulation technology and artificial intelligence. The platform analyzes cardiac computed tomography (CT) scans to create ‘digital twins’—virtual copies of a patient’s heart or its substructures. This technology goes beyond basic anatomical measurements, providing physicians with unprecedented, data-driven insights into how transcatheter structural heart devices will interact with a patient’s unique anatomy prior to a procedure.

For physicians, FEops HEARTguide™ offers a powerful tool to improve procedure efficiency and clinical outcomes. It enables more accurate predictions about device interactions, helping in the planning of transcatheter aortic valve implantation (TAVI) and left atrial appendage occlusion (LAAo) procedures, among others. The platform supports pre-operative planning by simulating different treatment scenarios, device sizes, and positions, thereby aiming to reduce complications like paravalvular leakage and conduction abnormalities. FEops is also working on extending its offering to peri-operative guidance, allowing physicians to visualize simulation results during interventions. Additionally, FEops provides services to medtech companies for device design exploration, performance assessment, and fatigue evaluation, contributing to faster and more cost-effective development of new implants.

Focus Areas

patient-specific computational modeling for cardiovascular interventions structural heart procedure planning (LAAO TAVI TMVR) medical image analysis CT-based segmentation computational biomechanics finite element analysis AI-enabled anatomical measurements landmark detection clinical validation outcomes research cloud-based clinical software collaborative platforms medtech device R&D design optimization digital twins

Business Intelligence

TechnologyCloud-based platform combining predictive simulation technology, artificial intelligence (AI), digital twin technology, finite element analysis (FEA), AI-driven CT image analysis, DICOM integration, 3D segmentation, multiplanar reconstruction (MPR), 3D interactive visualization

What Physicians Need to Know

Specialization
FEops nv specializes in personalized treatment planning for structural heart disease, focusing on Left Atrial Appendage Occlusion (LAAo) and Transcatheter Aortic Valve Implantation (TAVI) procedures.
Key Technology
Their core technology is the cloud-based platform, FEops HEARTguide™, which combines predictive simulation and AI-based anatomical analysis to create patient-specific digital twins of the heart.
LAAo Planning
For LAAo procedures, FEops HEARTguide™ provides unique insights to make procedures more predictable, helping physicians select optimal device size and position. Clinical evidence suggests it improves procedural efficiency, reduces complications, and increases complete LAA closure.
TAVI Planning
For TAVI planning, the platform enables better-informed decisions, especially in complex cases, by simulating device-anatomy interaction and predicting risks like paravalvular leak (PVL) and conduction abnormalities. It also offers insights for lifetime management, including future valve-in-valve procedures and coronary access assessment.
AI-based Anatomical Analysis
FEops HEARTguide™ includes an AI-based anatomical MSCT image analysis tool for pre-operative planning, which streamlines workflows by reducing the need for manual measurements while still allowing physicians to perform analysis themselves.
Predictive Simulation & Digital Twin
The platform utilizes patient-specific computational simulations, or digital twins, to predict how transcatheter structural heart devices will interact with a patient's unique anatomy before implantation.
Personalized Treatment
FEops is dedicated to revolutionizing personalized treatment for structural heart disease by providing data-driven insights that enhance procedure planning and periprocedural guidance.
Physician Tip

FEops HEARTguide™ offers interventional cardiologists a powerful tool to enhance procedural confidence and optimize outcomes. By leveraging AI-based anatomical analysis and predictive simulations, physicians can accurately assess device-anatomy interaction, select optimal device sizes and positions, and anticipate potential complications like paravalvular leaks or conduction abnormalities pre-operatively. This leads to more efficient procedures, reduced procedure and fluoroscopy times, and decreased contrast usage, particularly in LAAo interventions. The platform also supports long-term patient management by providing insights for future interventions, such as valve-in-valve procedures in TAVI. The ability to visualize and edit anatomical measurements, even with AI assistance, ensures physicians maintain control and understanding of the planning process.

FEops HEARTguide™ is a cloud-based platform, offering secure access, 3D visualization, DICOM ingestion, and case sharing capabilities. It integrates AI-driven simulation with 3D planning insights, and future developments aim to combine digital twin technology with fusion technologies for use in the catheterization laboratory, potentially assisting with device navigation during procedures. The platform is designed to be a collaborative environment, allowing secure case sharing with peers and industry partners.

Products by FEops nv

1 product in the directory

FEops HEARTguideTM
FEops
Cardiology AI
FEops HEARTguide™ is a cloud-based AI and digital twin platform for structural heart procedure planning, providing predictive simulations and anatomical insights to optimize device sizing and positioning for interventions like TAVI and LAAO.

What the Web Says

FEops nv is a company focused on healthcare technology, specifically known for its FEops HEARTguideTM product, which received clearance in 2023. While direct product reviews are limited, the company appears to be involved in clinical evidence review and utilizes AI in its operations. General sentiment regarding the company as an employer or its products is not widely available on major review platforms like G2, Glassdoor, Capterra, or Reddit.

Overall: Mixed

Strengths

  • FEops HEARTguideTM product received clearance in 2023
  • Involved in clinical evidence review
  • Utilizes AI in its operations

Limitations

  • Limited public reviews available on major platforms (G2, Glassdoor, Capterra, Reddit)
  • Specific product reviews are not readily found
  • Employer reviews are not widely available

Based on reviews from: Synapse, The Healthcare AI Institute / Transparency Registry

Last updated: 2026-10-18

Videos

News, demos, and interviews about FEops nv.

Loading videos...

Videos load interactively. If none appear, search YouTube for FEops nv →

View all on YouTube

Press & Coverage

Medical Device Network
FEops HEARTguide shows to boost LAAO procedure efficiency
A study demonstrated that FEops HEARTguide improved procedural efficiency in Left Atrial Appendage Occlusion (LAAO) procedures, reducing average procedure and fluoroscopy times.
2024-02-05
Business Wire
FEops Receives FDA Clearance for Its AI-Based Anatomical Analysis Capabilities
FEops announced FDA clearance for its new release of FEops HEARTguide™, which includes AI-based anatomical analysis of MSCT images for pre-operative planning of structural heart interventions.
2023-06-30
PubMed (JACC Adv.)
FEops HEARTguide Patient-Specific Computational Simulations for WATCHMAN FLX Left Atrial Appendage Closure: A Retrospective Study
This study demonstrated that the FEops HEARTguide platform accurately predicts WATCHMAN FLX device implantation characteristics for Left Atrial Appendage Closure.
2022-11-30
FEops Press Release
FEops HEARTguide receives FDA clearance for LAAo planning capabilities
FEops received FDA authorization for FEops HEARTguide™ for pre-operative planning of left atrial appendage occlusion (LAAo) with Abbott's Amplatzer™ Amulet™ and Boston Scientific's Watchman FLX™ devices.
2022-04-04
Business Wire
FEops HEARTguide Authorized by FDA for Unprecedented LAAo Planning Capabilities
FEops announced De Novo FDA authorization for FEops HEARTguide™ for pre-operative planning of left atrial appendage occlusion with the Boston Scientific WATCHMAN™ device.
2021-10-14
Business Wire
FEops HEARTguide combines digital twins and AI to revolutionize structural heart planning
FEops strengthened its position by introducing AI into its CE marked FEops HEARTguide platform, combining digital twin technology with AI-enabled anatomical analyses for structural heart interventions.
2021-05-27
CIO Applications
FEops | Top Simulation Solution Company-2021
FEops was recognized as a top simulation solution company for its patient-specific simulation technology for structural heart interventions, particularly its FEops HEARTguide™ solution.
2021-00
PubMed Central (BMC Cardiovasc Disord)
Value of FEops HEARTguide patient-specific computational simulations in the planning of left atrial appendage closure with the Amplatzer Amulet closure device: rationale and design of the PREDICT-LAA study
This article outlines the rationale and design of the PREDICT-LAA study, investigating the added value of FEops HEARTguide patient-specific computational simulations in planning LAA closure with the Amplatzer Amulet device.
2020-08-06

Frequently Asked Questions

FEops nv focuses on improving planning and outcomes for structural heart disease interventions, particularly in Left Atrial Appendage Occlusion (LAAo) and Transcatheter Aortic Valve Implantation (TAVI). Their technology aims to personalize treatment by providing physicians with predictive simulations and AI-based anatomical analysis, which can help in selecting the optimal device and procedure strategy for individual patients.
FEops nv's technology creates a 'digital twin' of a patient's anatomy, allowing for predictive simulations of different device implantations. This enables physicians to virtually test various scenarios, anticipate potential complications, and optimize device sizing and positioning before the actual procedure, thereby improving procedural success and patient safety in LAAo and TAVI.
FEops nv's flagship products include FEops HEARTguide, a cloud-based platform for pre-procedural planning of LAAo and TAVI. This platform uses AI-based anatomical analysis and predictive simulation to provide patient-specific insights. It is designed to integrate into existing clinical workflows by offering a user-friendly interface that complements current imaging and planning practices.
FEops nv's technology, FEops HEARTguide, has received CE mark and FDA clearance, indicating its compliance with European and US regulatory standards for medical devices. Clinical evidence supporting its effectiveness is gathered through various studies and real-world usage, demonstrating its utility in improving procedural planning and outcomes for structural heart interventions.
FEops nv typically offers its services on a per-procedure or subscription-based model, though specific pricing details would require direct inquiry. They provide comprehensive support and training to healthcare providers, including onboarding, technical assistance, and clinical education to ensure effective integration and utilization of their planning platforms.
FEops nv actively pursues partnerships with medical device manufacturers, research institutions, and healthcare providers to expand the reach and capabilities of its technology. The company demonstrates strong long-term stability, backed by successful funding rounds and a clear vision to become a leader in personalized structural heart disease treatment through continued innovation in AI and simulation technologies.

Related Companies

Caption Health, formerly known as Bay Labs and now part of GE HealthCare, is a pioneering medical artificial intelligence (AI) company dedicated to expanding access to high-quality ultrasound examinations. The company’s core offering is the Caption AI platform, which utilizes AI to guide healthcare providers, including those without extensive specialized training, in acquiring and interpreting […]

Anumana is an AI-driven health technology company dedicated to transforming cardiovascular care. Co-founded by nference and Mayo Clinic, Anumana develops software-as-a-medical-device (SaMD) solutions that leverage multimodal AI to support early detection, clinical decision-making, and intraoperative guidance across the continuum of care. The company’s portfolio includes FDA-cleared ECG-based algorithms, generative imaging applications, and real-time procedural support […]

Keya Medical Technology Co. is an international medical technology company specializing in deep learning-based AI solutions for non-invasive disease diagnosis and treatment. The company, founded in 2016, develops AI-enabled diagnostic devices that aim to enhance efficiency, accuracy, and precision in healthcare across various specialties, including cardiology, neurology, pulmonology, pathology, and surgery. [2, 4, 8, 14] […]

Siemens Medical Solutions USA, Inc., operating as Siemens Healthineers USA, is a prominent medical technology company with a rich history spanning over 175 years, dedicated to pioneering breakthroughs in healthcare. As a subsidiary of the global Siemens Healthineers AG, the company offers a comprehensive portfolio that is central to clinical decision-making across the entire healthcare […]

HeartLung.AI is a health-tech company focused on leveraging artificial intelligence for the early detection and prevention of cardiovascular disease and lung cancer. Their mission is to shift healthcare from late-stage disease treatment to earlier identification and prevention by unlocking clinically actionable information embedded within routine medical imaging. The company has developed several FDA-cleared and breakthrough-designated […]

Heartvue.ai is a healthcare AI company focused on transforming cardiovascular imaging analysis. Founded by a cardiologist with over two decades of experience in advanced cardiac imaging, the company develops AI-powered tools to make advanced cardiac imaging analysis more accessible, consistent, and efficient for healthcare systems. Their mission is to alleviate the burden of manual workflows […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.